View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 27, 2020

UQ’s Covid-19 vaccine shows effectiveness in preclinical studies

The University of Queensland (UQ) in Australia has reported positive data from preclinical tests of its Covid-19 vaccine candidate conducted by Viroclinics-DDL in the Netherlands.

The University of Queensland (UQ) in Australia has reported positive data from preclinical tests of its Covid-19 vaccine candidate conducted by Viroclinics-DDL in the Netherlands.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Data indicates the candidate’s effectiveness and manufacturability.

The vaccine reportedly generated neutralising immune response against Covid-19 in animal models.

In some animals, the candidate provided protection against virus replication and decreased lung inflammation, and generated a strong T-cell response.

Project co-leader associate professor Keith Chappell said: “The neutralising immune response created by our molecular clamp vaccine in animal models was better than the average level of antibodies found in patients who have recovered from Covid-19.

“In hamster models, the vaccine combined with the Seqirus MF59 adjuvant provided protection against virus replication and reduced lung inflammation following exposure to the virus.

“It also induces a strong T-cell response and showed strong results when it came to data relating to manufacturability.”

The university partnered with CSL for the manufacturing of its vaccine candidate. It estimates to produce millions of doses to protect the citizens in Australia.

CSL and UQ partnered in June to speed up the development, manufacture and distribution of the vaccine. CSL and the Coalition for Epidemic Preparedness Innovations (CEPI) agreed to fund development and manufacturing activities.

TetraQ, Australian National University (ANU), the University of Melbourne and the Peter Doherty Institute for Infection and Immunity are also performing the clinical work.

Researchers are conducting a Phase I clinical trial in Queensland. If successful, results could be available in time for CSL to launch a large-scale efficacy study before the end of the year.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology